Valotx
Helsinki, FI · Founded 2016 · 11 employees on LinkedIn · 1 known investors
ValoTx develops oncolytic virus-based immunotherapies that combine viral vector technology with peptide vaccination to treat cancer. The company leverages a patented platform to rapidly create personalized and disease-specific immunotherapies targeting multiple cancer types.
Investors · 1
Competitors · 3
by search overlapValo14 shared keywordsValo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields. It positions itself as a company focused on reshaping how new drugs are discovered.
Valora Therapeutics8 shared keywordsValora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications. Its work builds on glycobiology and bioorthogonal chemistry research.
flagship pioneering7 shared keywordsFlagship Pioneering is a firm that builds and funds companies in life sciences and related fields, describing itself as focused on breakthroughs for people and the planet.
Companies competing with Valotx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Valotx do?
- ValoTx develops oncolytic virus-based immunotherapies that combine viral vector technology with peptide vaccination to treat cancer. The company leverages a patented platform to rapidly create personalized and disease-specific immunotherapies targeting multiple cancer types.
- Who are Valotx's investors?
- Valotx's investors include CDP Venture Capital.
- Where is Valotx headquartered?
- Valotx is headquartered in Helsinki, FI.